At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 47 enrolled
Drug / intervention
Rituximab +1 moredrug
Likely dose
Rituximab 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG)
In Brief
A Phase 3 clinical trial evaluating Rituximab and Sodium Chloride solution for Generalized Myasthenia Gravis. Completed, enrolled 47 participants across 1 site.
Detailed Summary
A randomized, double-blind, placebo-controlled multicenter study evaluating the safety and efficacy of Rituximab (Mabthera®) in patients with new onset generalized myasthenia gravis (MG).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Myasthenia Gravis
CountriesSweden
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedOct 2016
Primary CompletionJan 2021
Study CompletionJan 2022
TodayJul 2026
First PostedOct 31, 2016
Enrollment StartOct 16, 2016
Primary CompletionJan 30, 2021
Study CompletionJan 31, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.7 years ago
Interventions
Rituximabdrug
A single infusion at a dose of 500 mg Mabthera/Rituximab.
Sodium Chloride solutiondrug
A single infusion of Placebo/Sham.